PDF(Pubmed)
Abstract：
Clinical differentiation of progressive supranuclear palsy (PSP) from Parkinson\'s disease (PD) is challenging due to overlapping phenotypes and the late onset of specific atypical signs. Therefore, easily assessable diagnostic biomarkers are highly needed. Since PD is a synucleopathy while PSP is a tauopathy, here, we investigated the clinical usefulness of serum oligomeric-α-synuclein (o-α-synuclein) and 181Thr-phosphorylated tau (p-tau181), which are considered as the most important pathological protein forms in distinguishing between these two parkinsonisms. We assessed serum o-α-synuclein and p-tau181 by ELISA and SIMOA, respectively, in 27 PSP patients, 43 PD patients, and 39 healthy controls (HC). Moreover, we evaluated the correlation between serum biomarkers and biological and clinical features of these subjects. We did not find any difference in serum concentrations of p-tau181 and o-α-synuclein nor in the o-α-synuclein/p-tau181 ratio between groups. However, we observed that serum p-tau181 positively correlated with age in HC and PD, while serum o-α-synuclein correlated positively with disease severity in PD and negatively with age in PSP. Finally, the o-α-synuclein/p-tau181 ratio showed a negative correlation with age in PD.
摘要：
进行性核上性麻痹（PSP）与帕金森病（PD）的临床鉴别具有挑战性，原因是表型重叠和特定非典型体征的迟发。因此,非常需要易于评估的诊断生物标志物.由于PD是突触核病，而PSP是tau蛋白病，在这里，我们调查了血清寡聚α-突触核蛋白（o-α-突触核蛋白）和181Thr-磷酸化tau（p-tau181）的临床有用性，这被认为是区分这两种帕金森病的最重要的病理蛋白形式。我们通过ELISA和SIMOA评估血清o-α-突触核蛋白和p-tau181，分别,在27名PSP患者中，43例PD患者,和39名健康对照（HC）。此外，我们评估了这些受试者的血清生物标志物与生物学和临床特征之间的相关性.我们没有发现两组之间p-tau181和o-α-突触核蛋白的血清浓度或o-α-突触核蛋白/p-tau181比率的任何差异。然而,我们观察到血清p-tau181与HC和PD的年龄呈正相关，而血清o-α-突触核蛋白与PD的疾病严重程度呈正相关，与PSP的年龄呈负相关。最后,o-α-突触核蛋白/p-tau181比值与年龄呈负相关。
